SRC and neoplasm: The RGD-mimetic cilengitide (EMD 121974) blocks the extracellular domain of αvβ3 and αvβ5 integrins from binding their ligands thereby inhibiting the downstream signalling of FAK/Src/Akt and induces apoptosis in endothelial cells and some tumor cells [5].